Literature DB >> 12844323

What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia.

Peter Schulte1.   

Abstract

Clozapine is the gold standard and 'last resort' in treatment of refractory schizophrenia. It is important to know whether a trial with clozapine is adequate or not. Six studies show a significantly higher response rate at clozapine plasma trough levels above a therapeutic threshold of 350-400 micro g/L. The absolute risk reduction is about 40%. An additional study found best results with plasma levels between 300 and 700 micro g/L, and one (probably too small) study could not detect a significantly different response rate for 350-450 micro g/L in comparison to 200-300 micro g/L. In addition, two extension studies showed conversion from nonresponders to responders if plasma levels increased above the threshold. Investigations on time to response in treatment with clozapine are often hampered by not controlling for time until plateau of dose titration or clozapine concentration. One of the better studies found 34 responders within 8 weeks after the last dose escalation. The remaining 16 non-responding patients did not change their status during a mean follow-up of 75 weeks. A second 1 year trial found a superior differential response rate for clozapine in comparison to haloperidol only during the first 6 weeks. A third study combined regular clozapine plasma level assays with assessment of response status. At the time of response 17 out of 19 responders showed clozapine concentrations above 350 micro g/L. The nine non-responders remained below this threshold throughout the rest of the year. These results favour an approach of raising the clozapine plasma level in treatment-refractory schizophrenic patients who do not respond to an initial low-to-medium dose treatment with clozapine. Some patients, especially young male smokers, will need dosages higher than 900 mg/day. Addition of low-dose fluvoxamine while closely monitoring clozapine levels can help decrease the high number of necessary pills. An adequate trial with clozapine should last at least 8 weeks on a plasma trough level above 350-400 micro g/L.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12844323     DOI: 10.2165/00003088-200342070-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  69 in total

1.  Branded versus generic clozapine: bioavailability comparison and interchangeability issues.

Authors:  Y W Lam; L Ereshefsky; G B Toney; C Gonzales
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

2.  Efficacy of medium-dose clozapine for treatment-resistant schizophrenia.

Authors:  M Kurz; M Hummer; I Kurzthaler; H Oberbauer; W W Fleischhacker
Journal:  Am J Psychiatry       Date:  1995-11       Impact factor: 18.112

3.  Therapeutic effect of clozapine at an unusually high plasma level.

Authors:  B Trappler; V Kwong; C P Leeman
Journal:  Am J Psychiatry       Date:  1996-01       Impact factor: 18.112

4.  Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients.

Authors:  M H Kronig; R A Munne; S Szymanski; A Z Safferman; S Pollack; T Cooper; J M Kane; J A Lieberman
Journal:  Am J Psychiatry       Date:  1995-02       Impact factor: 18.112

5.  Coadministration of clozapine and fluvoxamine in psychotic patients--clinical experience.

Authors:  C H Lammers; M Deuschle; H Weigmann; S Härtter; C Hiemke; C Heese; I Heuser
Journal:  Pharmacopsychiatry       Date:  1999-03       Impact factor: 5.788

6.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

Review 7.  Will routine therapeutic drug monitoring have a place in clozapine therapy?

Authors:  D J Freeman; L K Oyewumi
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

8.  Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response.

Authors:  S C Piscitelli; J A Frazier; K McKenna; K E Albus; D R Grothe; C T Gordon; J L Rapoport
Journal:  J Clin Psychiatry       Date:  1994-09       Impact factor: 4.384

9.  Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine.

Authors:  D Pickar; R R Owen; R E Litman; E Konicki; R Gutierrez; M H Rapaport
Journal:  Arch Gen Psychiatry       Date:  1992-05

Review 10.  Therapeutic drug monitoring of clozapine treatment. Therapeutic threshold value for serum clozapine concentrations.

Authors:  O V Olesen
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

View more
  25 in total

Review 1.  Clinical Pharmacokinetics of Atypical Antipsychotics: An Update.

Authors:  Massimo Carlo Mauri; Silvia Paletta; Chiara Di Pace; Alessandra Reggiori; Giovanna Cirnigliaro; Isabel Valli; Alfredo Carlo Altamura
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

2.  Genetic and Clinical Factors Affecting Plasma Clozapine Concentration.

Authors:  Eric Olsson; Gunnar Edman; Leif Bertilsson; Dzana Sudic Hukic; Catharina Lavebratt; Sven V Eriksson; Urban Ösby
Journal:  Prim Care Companion CNS Disord       Date:  2015-02-19

Review 3.  Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review.

Authors:  Iris E Sommer; Marieke J H Begemann; Anke Temmerman; Stefan Leucht
Journal:  Schizophr Bull       Date:  2011-03-21       Impact factor: 9.306

4.  Dopamine and serotonin metabolism in response to chronic administration of fluvoxamine and haloperidol combined treatment.

Authors:  Y Chertkow; O Weinreb; M B H Youdim; H Silver
Journal:  J Neural Transm (Vienna)       Date:  2007-06-18       Impact factor: 3.575

5.  Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats.

Authors:  SuJean Choi; Briana DiSilvio; JayLynn Unangst; John D Fernstrom
Journal:  Life Sci       Date:  2007-08-17       Impact factor: 5.037

Review 6.  Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response.

Authors:  Massimo C Mauri; Lucia S Volonteri; Alessandro Colasanti; Alessio Fiorentini; Ilaria F De Gaspari; Silvio R Bareggi
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 7.  Worldwide Differences in Regulations of Clozapine Use.

Authors:  Jimmi Nielsen; Corina Young; Petru Ifteni; Taishiro Kishimoto; Yu-Tao Xiang; Peter F J Schulte; Christoph U Correll; David Taylor
Journal:  CNS Drugs       Date:  2016-02       Impact factor: 5.749

Review 8.  The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses.

Authors:  Peter M Haddad; Christoph U Correll
Journal:  Ther Adv Psychopharmacol       Date:  2018-10-08

Review 9.  Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?

Authors:  Gary Remington; Ofer Agid; George Foussias; Larissa Ferguson; Krysta McDonald; Valerie Powell
Journal:  Psychopharmacology (Berl)       Date:  2012-11-22       Impact factor: 4.530

10.  Current perspectives in the treatment of resistant schizophrenia.

Authors:  R K Solanki; Paramjeet Singh; Deepti Munshi
Journal:  Indian J Psychiatry       Date:  2009 Oct-Dec       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.